GlassScriptPhysician profile
Laura M Erdman
NPI 1265438238
$3,637.33
in general payments reported to CMS, 2019-2025
34 companies · $615 in 2025
The $615 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $463 · 2021: $383 · 2022: $615 · 2023: $429 · 2024: $684 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.68 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $395.56 | 2021-2025 | Nexplanon |
| Abbvie INC. | $326.69 | 2019-2024 | |
| Hologic Sales and Service, LLC | $233.19 | 2021-2025 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Astellas Pharma US INC | $219.76 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $191.72 | 2021-2025 | |
| Pfizer INC. | $186.49 | 2021-2025 | |
| Myovant Sciences INC. | $183.37 | 2021-2022 | |
| Avion Pharmaceuticals | $168.58 | 2019-2021 | |
| Therapeuticsmd, INC. | $164.37 | 2019-2022 | |
| Exeltis, USA INC. | $153.46 | 2019-2025 | Slynd |
| Daiichi Sankyo INC. | $147.43 | 2020-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $136.21 | 2020-2025 | |
| Coopersurgical, INC. | $116.48 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Sage Therapeutics, LLC | $115.70 | 2022-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $103.31 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $102.72 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $102.70 | 2019-2021 | |
| Aspira Women'S Health INC | $68.77 | 2023-2024 | Ova1 |
| Evofem Biosciences, INC. | $63.61 | 2021-2025 | Solosec, Phexx, Phexxi |
| Allergan, INC. | $59.10 | 2019-2020 | |
| Scynexis, INC. | $47.97 | 2022 | |
| Shield Therapeutics INC | $47.39 | 2023 | Accrufer |
| Millicent US INC | $45.47 | 2019-2023 | Femring |
| Innovation Technologies INC | $41.21 | 2022 | |
| Duchesnay USA Incorporated | $39.65 | 2019 | |
| Supernus Pharmaceuticals, INC. | $35.48 | 2025 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $25.75 | 2022 | |
| Lupin INC. | $24.35 | 2020 | |
| Agile Therapeutics, INC. | $19.19 | 2021 | |
| Ethicon US, LLC | $19.12 | 2025 | Enseal |
| Smith+Nephew, INC. | $18.70 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.66 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $16.17 | 2023 | Vivjoa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Erdman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.